BICX - BioCorRx gets review board nod to begin phase 1 trial of BICX104 for opioid use disorder

BioCorRx (OTCQB:BICX) received approval from an independent institutional review board to begin a phase 1 trial of its therapy BICX104, an implantable biodegradable naltrexone pellet to treat opioid use disorder. Naltrexone is used to manage alcohol or opioid use disorder by reducing cravings and feelings. "BICX104 is being developed with the goal of improving patient compliance to naltrexone therapy compared to other marketed pharmacotherapies," said BioCorRx President and Director Brady Granier. The phase 1 study will enroll healthy people to evaluate BICX104 implantable subcutaneous naltrexone pellets and the marketed once a month intramuscular depot naltrexone injection. The company said BICX104 is being developed in partnership with the National Institute on Drug Abuse, which is a part of the National Institutes of Health.

For further details see:

BioCorRx gets review board nod to begin phase 1 trial of BICX104 for opioid use disorder